Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in neutrophils | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 60 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 9919
Sealed predictions
- RNF13 in oligodendrocytes, braak+0.59 (p 0.096) → +0.59 (p 0.095)receipt 9926
- RNF13 in dopamine neurons, braak+0.78 (p 0.013) → +0.58 (p 0.102)receipt 9927
Swarm cases
receipt 9927: RNF13 in dopamine neurons, braak
- power
- full sample +0.72 (p 8.2e-4, n 18), 95% CI +0.38 to +0.89. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.74 (p 4.2e-4, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.77 (p 1.8e-4, n 18). not the mix.
- skeptic
- leave-one-out range +0.68 to +0.81, sign flips 0; without severely affected donors +0.72 (p 8.2e-4, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF13 in dopamine neurons.
case closed: nothing better to follow up.
receipt 9926: RNF13 in oligodendrocytes, braak
- power
- full sample +0.56 (p 0.017, n 18), 95% CI +0.12 to +0.81. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.58 (p 0.013, n 18). holds up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.68 (p 0.0017, n 18). not the mix.
- skeptic
- leave-one-out range +0.50 to +0.63, sign flips 0; without severely affected donors +0.56 (p 0.017, n 18). robust.
- cell type
- strongest in dopamine neurons: +0.72 (p 8.2e-4, n 18) vs +0.56 in oligodendrocytes. proposing dopamine neurons.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF13 in oligodendrocytes.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RNF13 · dopamine neurons · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 2.2e-4)
Receipts
loading the receipts